Reviews Ioxilan


No reviews yet.

Oxilan Drug Description
OXILAN®
(ioxilan) Injection 300 mgl/mL
OXILAN®
(ioxilan) Injection 350 mgI/mL
Nonionic Contrast Agents
NOT FOR INTRATHECAL USE
DRUG DESCRIPTION
OXILAN® (loxilan Injection) formulations are stable, aqueous, sterile, and non-pyrogenic solutions for intravascular administration as diagnostic radiopaque media. Ioxilan is designated chemically as N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide and has the following structural formula:







The molecular weight of Ioxilan is 791.12 and the organically bound iodine content is 48.1%. loxilan is nonionic and does not dissociate in solution.
Each mL of OXILAN® (loxilan Injection) 300 mgl/mL provides 623 mg ioxilan.
Each mL of OXILAN® (Ioxilan Injection) 350 mgI/mL provides 727 mg ioxilan.
Each mL of OXILAN® solution contains 0.576 mg citric acid anhydrous, 0.561
mg edetate calcium disodium, and a minimum of 0.22 mg (0.01 mEq) sodium. The
pH is adjusted to 6.8 (6.0 to 7.5) with sodium hydroxide and carbon dioxide.
The solutions contain no preservative.
Pertinent physicochemical data are below. OXILAN® (Ioxilan Injection) is
hypertonic compared to plasma (approximately 285 mOsnVkg water).



Concentration (mgI/mL)
Concentration W/V


300
350


Measured Osmolality (mOsm/kg water) @ 37°C
585
695


Viscosity (cPs)
    @ 37°C
    @ 20°C

5.1
9.4

8.1
16.3


Specific Gravity @ 37°C
1.303
1.372



The OXILAN® formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. OXILAN® solutions have osmolalities of 2.1 and 2.4 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use.
Last reviewed on RxList: 2/25/2009




Oxilan Drug Description
OXILAN®
(ioxilan) Injection 300 mgl/mL
OXILAN®
(ioxilan) Injection 350 mgI/mL
Nonionic Contrast Agents
NOT FOR INTRATHECAL USE
DRUG DESCRIPTION
OXILAN® (loxilan Injection) formulations are stable, aqueous, sterile, and non-pyrogenic solutions for intravascular administration as diagnostic radiopaque media. Ioxilan is designated chemically as N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide and has the following structural formula:







The molecular weight of Ioxilan is 791.12 and the organically bound iodine content is 48.1%. loxilan is nonionic and does not dissociate in solution.
Each mL of OXILAN® (loxilan Injection) 300 mgl/mL provides 623 mg ioxilan.
Each mL of OXILAN® (Ioxilan Injection) 350 mgI/mL provides 727 mg ioxilan.
Each mL of OXILAN® solution contains 0.576 mg citric acid anhydrous, 0.561
mg edetate calcium disodium, and a minimum of 0.22 mg (0.01 mEq) sodium. The
pH is adjusted to 6.8 (6.0 to 7.5) with sodium hydroxide and carbon dioxide.
The solutions contain no preservative.
Pertinent physicochemical data are below. OXILAN® (Ioxilan Injection) is
hypertonic compared to plasma (approximately 285 mOsnVkg water).



Concentration (mgI/mL)
Concentration W/V


300
350


Measured Osmolality (mOsm/kg water) @ 37°C
585
695


Viscosity (cPs)
    @ 37°C
    @ 20°C

5.1
9.4

8.1
16.3


Specific Gravity @ 37°C
1.303
1.372



The OXILAN® formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. OXILAN® solutions have osmolalities of 2.1 and 2.4 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use.
Last reviewed on RxList: 2/25/2009




Oxilan Drug Description
OXILAN®
(ioxilan) Injection 300 mgl/mL
OXILAN®
(ioxilan) Injection 350 mgI/mL
Nonionic Contrast Agents
NOT FOR INTRATHECAL USE
DRUG DESCRIPTION
OXILAN® (loxilan Injection) formulations are stable, aqueous, sterile, and non-pyrogenic solutions for intravascular administration as diagnostic radiopaque media. Ioxilan is designated chemically as N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide and has the following structural formula:







The molecular weight of Ioxilan is 791.12 and the organically bound iodine content is 48.1%. loxilan is nonionic and does not dissociate in solution.
Each mL of OXILAN® (loxilan Injection) 300 mgl/mL provides 623 mg ioxilan.
Each mL of OXILAN® (Ioxilan Injection) 350 mgI/mL provides 727 mg ioxilan.
Each mL of OXILAN® solution contains 0.576 mg citric acid anhydrous, 0.561
mg edetate calcium disodium, and a minimum of 0.22 mg (0.01 mEq) sodium. The
pH is adjusted to 6.8 (6.0 to 7.5) with sodium hydroxide and carbon dioxide.
The solutions contain no preservative.
Pertinent physicochemical data are below. OXILAN® (Ioxilan Injection) is
hypertonic compared to plasma (approximately 285 mOsnVkg water).



Concentration (mgI/mL)
Concentration W/V


300
350


Measured Osmolality (mOsm/kg water) @ 37°C
585
695


Viscosity (cPs)
    @ 37°C
    @ 20°C

5.1
9.4

8.1
16.3


Specific Gravity @ 37°C
1.303
1.372



The OXILAN® formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. OXILAN® solutions have osmolalities of 2.1 and 2.4 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use.
Last reviewed on RxList: 2/25/2009




Oxilan Drug Description
OXILAN®
(ioxilan) Injection 300 mgl/mL
OXILAN®
(ioxilan) Injection 350 mgI/mL
Nonionic Contrast Agents
NOT FOR INTRATHECAL USE
DRUG DESCRIPTION
OXILAN® (loxilan Injection) formulations are stable, aqueous, sterile, and non-pyrogenic solutions for intravascular administration as diagnostic radiopaque media. Ioxilan is designated chemically as N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide and has the following structural formula:







The molecular weight of Ioxilan is 791.12 and the organically bound iodine content is 48.1%. loxilan is nonionic and does not dissociate in solution.
Each mL of OXILAN® (loxilan Injection) 300 mgl/mL provides 623 mg ioxilan.
Each mL of OXILAN® (Ioxilan Injection) 350 mgI/mL provides 727 mg ioxilan.
Each mL of OXILAN® solution contains 0.576 mg citric acid anhydrous, 0.561
mg edetate calcium disodium, and a minimum of 0.22 mg (0.01 mEq) sodium. The
pH is adjusted to 6.8 (6.0 to 7.5) with sodium hydroxide and carbon dioxide.
The solutions contain no preservative.
Pertinent physicochemical data are below. OXILAN® (Ioxilan Injection) is
hypertonic compared to plasma (approximately 285 mOsnVkg water).



Concentration (mgI/mL)
Concentration W/V


300
350


Measured Osmolality (mOsm/kg water) @ 37°C
585
695


Viscosity (cPs)
    @ 37°C
    @ 20°C

5.1
9.4

8.1
16.3


Specific Gravity @ 37°C
1.303
1.372



The OXILAN® formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. OXILAN® solutions have osmolalities of 2.1 and 2.4 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use.
Last reviewed on RxList: 2/25/2009




Oxilan Drug Description
OXILAN®
(ioxilan) Injection 300 mgl/mL
OXILAN®
(ioxilan) Injection 350 mgI/mL
Nonionic Contrast Agents
NOT FOR INTRATHECAL USE
DRUG DESCRIPTION
OXILAN® (loxilan Injection) formulations are stable, aqueous, sterile, and non-pyrogenic solutions for intravascular administration as diagnostic radiopaque media. Ioxilan is designated chemically as N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide and has the following structural formula:







The molecular weight of Ioxilan is 791.12 and the organically bound iodine content is 48.1%. loxilan is nonionic and does not dissociate in solution.
Each mL of OXILAN® (loxilan Injection) 300 mgl/mL provides 623 mg ioxilan.
Each mL of OXILAN® (Ioxilan Injection) 350 mgI/mL provides 727 mg ioxilan.
Each mL of OXILAN® solution contains 0.576 mg citric acid anhydrous, 0.561
mg edetate calcium disodium, and a minimum of 0.22 mg (0.01 mEq) sodium. The
pH is adjusted to 6.8 (6.0 to 7.5) with sodium hydroxide and carbon dioxide.
The solutions contain no preservative.
Pertinent physicochemical data are below. OXILAN® (Ioxilan Injection) is
hypertonic compared to plasma (approximately 285 mOsnVkg water).



Concentration (mgI/mL)
Concentration W/V


300
350


Measured Osmolality (mOsm/kg water) @ 37°C
585
695


Viscosity (cPs)
    @ 37°C
    @ 20°C

5.1
9.4

8.1
16.3


Specific Gravity @ 37°C
1.303
1.372



The OXILAN® formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. OXILAN® solutions have osmolalities of 2.1 and 2.4 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use.
Last reviewed on RxList: 2/25/2009





Other reviews about Ioxilan on web:

Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name ... Ioxilan - Wikipedia, the free encyclopedia


Learn about the prescription medication Oxilan (Ioxilan), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Oxilan (Ioxilan) Drug Information: Uses, Side Effects, Drug ...


ioxilan /ioxテδづつキiテδづつキlan/ (i-okテδづつエsテδテつュ-lan) a low-viscosity, low-osmolality, nonionic contrast agent used in arteriography, excretory urography, and computed tomography. ioxilan - definition of ioxilan in the Medical dictionary - by the ...


Learn more about Ioxilan. Find the Web's best health guides, medical reports, news, videos and tools for Ioxilan. Share Ioxilan experiences and get advice from experts. Ioxilan Overview - References, Advice, News, Videos, Coping & Support


Copy & paste this link to your blog or website to reference this page Ioxilan encyclopedia topics | Reference.com


Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. Ioxilan - Kosmix : Reference, Videos, Images, News, Shopping and ...


Ioxilan information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues. Ioxilan - WrongDiagnosis.com


Chemical name: N-(2,3-dihydroxypropyl)-N テδづつエ-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide : Abbreviated name: Ioxilan N-(2,3-Dihydroxypropyl)-Nテδづつエ-(2-hydroxyethyl)-5-[N-(2,3 ...


Ioxilan Drug Information from Drugs.com. Includes Ioxilan side effects, interactions and indications. Ioxilan Drug Information, Professional


Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. About: Ioxilan





Featured Reviews

Reviews Calcium Disodium Versenate

Calcium Disodium Versenate Drug Description Calcium Disodium Versenate (edetate calcium disodium) Injection,USP WARNINGS: Calcium Disodium Versenate is capable of producing toxic effects which can be fatal. Lead encephalopathy is relatively...
Read More  |  Review This
Reviews Relistor

Relistor Drug Description RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection DRUG DESCRIPTION What are the possible side effects of methylnaltrexone (Relistor)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Altace

Altace Drug Description Altace® (ramipril) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is...
Read More  |  Review This
Reviews Clemastine Fumarate Tablets

Clemastine Fumarate Tablets Drug Description Clemastine Fumarate Tablets, USP DRUG DESCRIPTION Clemastine fumarate belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-2-[-2- [(p-chloro- α-methyl-&al...
Read More  |  Review This
Reviews Megestrol Acetate

Megace Drug Description Megace® (megestrol acetate, USP) Oral Suspension DRUG DESCRIPTION What are the possible side effects of megestrol (Megace)? Stop taking megestrol and seek emergency medical attention or call your doctor...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....